This topic contains a solution. Click here to go to the answer

Author Question: Potassium-40 decays to argon-40 with a half-life of 1.27 109 yr. The age of a mineral sample that ... (Read 127 times)

scienceeasy

  • Hero Member
  • *****
  • Posts: 565
Potassium-40 decays to argon-40 with a half-life of 1.27  109 yr. The age of a mineral sample that has a mass ratio of 40Ar to 40K of 0.330 is ________ yr.
 
  A) 3.85  109
  B) 1.77  109
  C) 2.55  109
  D) 3.62  108
  E) 5.23  108

Question 2

Which point on the cooling curve corresponds to the freezing point of paradichlorobenzene?
 
  A) the lowest point on the curve
  B) the highest point on the curve
  C) the flat portion of the curve
  D) the midpoint of the curve
  E) the final point on the curve



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

prumorgan

  • Sr. Member
  • ****
  • Posts: 326
Answer to Question 1

E

Answer to Question 2

C)




scienceeasy

  • Member
  • Posts: 565
Reply 2 on: Aug 27, 2018
Great answer, keep it coming :)


yeungji

  • Member
  • Posts: 319
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Cancer has been around as long as humankind, but only in the second half of the twentieth century did the number of cancer cases explode.

Did you know?

The heart is located in the center of the chest, with part of it tipped slightly so that it taps against the left side of the chest.

Did you know?

Signs of depression include feeling sad most of the time for 2 weeks or longer; loss of interest in things normally enjoyed; lack of energy; sleep and appetite disturbances; weight changes; feelings of hopelessness, helplessness, or worthlessness; an inability to make decisions; and thoughts of death and suicide.

Did you know?

Addicts to opiates often avoid treatment because they are afraid of withdrawal. Though unpleasant, with proper management, withdrawal is rarely fatal and passes relatively quickly.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library